- Home
- MDIA vs NVNO Comparison
MDIA vs NVNO Comparison
Compare MDIA & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- NVNO
- Stock Information
- Founded
- MDIA 2019
- NVNO 1987
- Country
- MDIA United States
- NVNO United States
- Employees
- MDIA N/A
- NVNO N/A
- Industry
- MDIA Broadcasting
- NVNO Medical/Dental Instruments
- Sector
- MDIA Consumer Discretionary
- NVNO Health Care
- Exchange
- MDIA Nasdaq
- NVNO Nasdaq
- Market Cap
- MDIA 53.9M
- NVNO 62.4M
- IPO Year
- MDIA N/A
- NVNO N/A
- Fundamental
- Price
- MDIA $1.16
- NVNO $3.77
- Analyst Decision
- MDIA
- NVNO
- Analyst Count
- MDIA 0
- NVNO 0
- Target Price
- MDIA N/A
- NVNO N/A
- AVG Volume (30 Days)
- MDIA 31.9K
- NVNO 99.9K
- Earning Date
- MDIA 03-31-2025
- NVNO 03-03-2025
- Dividend Yield
- MDIA N/A
- NVNO N/A
- EPS Growth
- MDIA N/A
- NVNO N/A
- EPS
- MDIA N/A
- NVNO N/A
- Revenue
- MDIA $69,296,000.00
- NVNO N/A
- Revenue This Year
- MDIA N/A
- NVNO N/A
- Revenue Next Year
- MDIA N/A
- NVNO N/A
- P/E Ratio
- MDIA N/A
- NVNO N/A
- Revenue Growth
- MDIA 94.96
- NVNO N/A
- 52 Week Low
- MDIA $0.40
- NVNO $2.45
- 52 Week High
- MDIA $6.86
- NVNO $6.97
- Technical
- Relative Strength Index (RSI)
- MDIA 50.86
- NVNO 67.71
- Support Level
- MDIA $1.12
- NVNO $3.48
- Resistance Level
- MDIA $1.20
- NVNO $3.80
- Average True Range (ATR)
- MDIA 0.07
- NVNO 0.26
- MACD
- MDIA 0.00
- NVNO 0.06
- Stochastic Oscillator
- MDIA 63.89
- NVNO 90.80
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).